4-Pyridone-3-carboxamide-1-β-D-ribonucleoside Triphosphate (4PyTP), a Novel NAD+ Metabolite Accumulating in Erythrocytes of Uremic Children: A Biomarker for a Toxic NAD+ Analogue in Other Tissues? by Synesiou, Elena et al.
Toxins 2011, 3, 520-537; doi:10.3390/toxins3060520 
 
toxins
ISSN 2072-6651 
www.mdpi.com/journal/toxins 
Article 
4-Pyridone-3-carboxamide-1-β-D-ribonucleoside Triphosphate 
(4PyTP), a Novel NAD
+ Metabolite Accumulating in 
Erythrocytes of Uremic Children: A Biomarker for a Toxic 
NAD
+ Analogue in Other Tissues? 
Elena Synesiou 
1, Lynnette D. Fairbanks 
2, H. Anne Simmonds 
2,†, Ewa M. Slominska 
3,  
Ryszard T. Smolenski 
3 and Elizabeth A. Carrey 
1,* 
1  University College London Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK 
2  Purine Research Laboratory, Chemical Pathology Department, St Thomas’ Hospital, London SE1 
7EH, UK; E-Mail: Lynette.Fairbanks@gsts.com (L.D.F.) 
3  Department of Biochemistry, Medical University of Gdansk, Debinki 1, 80-211 Gdansk, Poland;  
E-Mails: eslom@gumed.edu.pl (E.M.S.); rt.smolenski@gmail.com (R.T.S.) 
†  Deceased on 2 April 2010.  
*  Author to whom correspondence should be addressed; E-Mail: lizcarrey@gmail.com. 
Received: 25 March 2011; in revised form: 13 May 2011 / Accepted: 31 May 2011 /  
Published: 7 June 2011  
 
Abstract:  We  have  identified  a  novel  nucleotide,  4-pyridone  3/5-carboxamide 
ribonucleoside triphosphate (4PyTP), which accumulates in human erythrocytes during 
renal failure. Using plasma and erythrocyte extracts obtained from children with chronic 
renal  failure  we  show  that  the  concentration  of  4PyTP  is  increased,  as  well  as other 
soluble NAD
+ metabolites (nicotinamide, N
1-methylnicotinamide and 4Py-riboside) and 
the  major  nicotinamide  metabolite  N
1-methyl-2-pyridone-5-carboxamide  (2PY),  with 
increasing degrees of renal failure. We noted that 2PY concentration was highest in the 
plasma of haemodialysis patients, while 4PyTP was highest in erythrocytes of children 
undergoing peritoneal dialysis: its concentration correlated closely with 4Py-riboside, an 
authentic precursor of 4PyTP, in the plasma. In the dialysis patients, GTP concentration 
was  elevated:  similar  accumulation  was  noted  previously,  as  a  paradoxical  effect  in 
erythrocytes  during  treatment  with  immunosuppressants  such  as  ribavirin  and 
mycophenolate mofetil, which deplete GTP through inhibition of IMP dehydrogenase in 
nucleated cells such as lymphocytes. We predict that 4Py-riboside and 4Py-nucleotides 
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bind  to  this  enzyme  and  alter  its  activity.  The  enzymes  that  regenerate  NAD
+  from 
nicotinamide  riboside  also  convert  the  drugs  tiazofurin  and  benzamide  riboside  into 
NAD
+  analogues  that  inhibit  IMP  dehydrogenase  more  effectively  than  the  related 
ribosides: we therefore propose that the accumulation of 4PyTP in erythrocytes during 
renal  failure is a marker  for the accumulation of a related toxic NAD
+ analogue that 
inhibits IMP dehydrogenase in other cells.  
Keywords:  uremia;  erythrocytes;  pyridone;  NAD
+;  4-pyridone  3/5-carboxamide 
ribonucleoside  triphosphate  (4PyTP);  nicotinamide  riboside  (NR);  IMP  dehydrogenase; 
HPLC 
Abbreviations:  2PY  and  4PY,  N
1-methyl-2-pyridone-5-carboxamide  and  N
1-methyl-4-
pyridone-3/5-carboxamide;  4KNTP,  4-ketonicotinamide  riboside  triphosphate  alias 
4PyTP;  4Py-riboside,  the  N
1-ribonucleoside  of  4-pyridone-3/5-carboxamide;  4PyTP, 
4PyDP,  4PyMN,  the  triphosphate,  diphosphate  and  mononucleotide  of  4-pyridone-3/5-
carboxamide-1β-D-ribonucleoside;  GFR,  glomerular  filtration  rate  for  creatinine;  HD, 
(mechanical)  haemodialysis;  IMPDH,  inosine  monophosphate  dehydrogenase,  
(EC  1.1.1.205,  IMP:NAD  oxidoreductase);  N-Me-nic,  N
1-methylnicotinamide;  NAD
+, 
nicotinamide adenine dinucleotide; NMN, nicotinamide mononucleotide; NR, nicotinamide 
riboside; PCNR, 4-pyridone carboxamide ribonucleoside (alias 4Py-riboside); PD, patients 
undergoing continuous ambulatory peritoneal dialysis; r, Pearson correlation coefficient 
 
1. Introduction  
The  nicotinamide  catabolite  N
1-methyl-2-pyridone-5-carboxamide  (2PY),  derived  from  the 
breakdown of NAD
+ during natural turnover and in response to DNA damage [1], is found in the urine 
of normal people, and also at high concentrations in the plasma of patients with renal failure [2]. We 
reported previously that a novel pyridone nucleotide, detectable in erythrocytes of healthy people, also 
accumulates to high concentrations in end-stage renal failure, and may reach concentrations of 0.5 mM 
in the erythrocytes of adult patients receiving renal replacement therapy [3]. The nucleotide elutes after 
ATP in our anion-exchange HPLC profiles, and has a characteristic UV absorption spectrum similar but 
not identical to that of 2PY [4]. The natural compound (tentatively named 2PyTP [3]) has now been 
identified unequivocally as the N
1-riboside triphosphate of 4-pyridone 3/5-carboxamide (4PyTP) [5], 
earlier also named by us as 4-ketonicotinamide riboside triphosphate or 4KNTP [6]. 
In  this  study  we  measured  the  concentrations  of  2PY  (principally  in  plasma)  and  4PyTP  (in 
erythrocytes) in children with uncomplicated mild to severe chronic renal failure. A preliminary report 
of  some  of  these  data  has  been  presented  [6].  We  have  subsequently  measured  several  putative 
biosynthetic precursors in plasma and erythrocytes, and it is now clear that 2PY and 4PyTP are derived 
from  NAD
+  by  distinct  degradation  pathways.  Both  are  biomarkers  of  the  oxidative  stress  that 
accompanies renal failure, and their accumulation is a result of poor filtration by the failing kidney. Toxins 2011, 3                    
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More importantly, metabolites of 4Py-riboside within other tissues may inhibit several enzymes that 
are crucial for cell division and proliferation.  
2. Materials and Methods  
2.1. Patients with Renal Failure 
Children aged 8–17 attending regular out-patient renal clinics or the haemodialysis unit of Great 
Ormond Street Hospital for Children (GOSH) were invited to provide a small blood sample, after they 
or their parents had given informed consent. Approval for the study was given by the GOSH Research 
Ethics Committee. The children (18 girls, 16 boys) had mild to severe chronic renal failure, with no 
other known metabolic disorder. Recruitment of a further 5 children undergoing peritoneal dialysis 
was subsequently permitted by the same Research Ethics Committee. 
Glomerular filtration rate (GFR, mL/min/1.73 m
2) in out-patients not receiving artificial dialysis 
was calculated from the creatinine concentrations in samples of plasma taken on the same occasion and 
assayed  by  the  Chemical  Pathology  laboratories  at  Great  Ormond  Street  Hospital.  The  National 
Kidney Foundation paediatric GFR calculator [7] was used: this takes account of the height, age and 
sex of the child to give a calculated value that is very close to the actual value [8]. The reference value 
for normal function is a GFR above 75 mL/min/1.73 m
2 [8]. Of the 34 patients, twelve children were in 
end-stage  renal  failure,  defined  as  GFR  <  10  mL/min/1.73  m
2:  six  patients  were  attending  the 
Haemodialysis  Unit  three  times  per  week  (HD),  and  six  were  receiving  continuous  ambulatory 
peritoneal dialysis (PD). 
2.2. Processing of Blood Samples for Liquid Chromatography  
Aliquots of 1 mL heparinised blood were centrifuged at 15,800 g in a microcentrifuge within two 
hours  of  venepuncture:  the  plasma  was  removed  and  retained,  and  the  top  one-fifth  of  the  cells, 
containing lymphocytes and platelets, was discarded. Washing of cells and extraction of erythrocytes 
and plasma by trichloroacetic acid were performed as described previously [3]. Water used in all 
solutions was freshly double-distilled, and buffers were de-gassed before use, ensuring a very low 
base-line with a modest rise of absorbance with increasing pH. The extracts were analysed by liquid 
chromatography with UV diode array analysis (230–310 nm) as described previously [3]: typically we 
used anion-exchange HPLC for erythrocyte extracts and reversed-phase HPLC for plasma extracts. A 
mixture of 17 authentic standards was run before each batch of samples, and conditions (gradient or 
elution rate) were adjusted to ensure separation of all the nucleotides and nucleosides of interest.  
Concentrations (µ M) of the compounds in the cytoplasm of the erythrocytes were calculated using 
the known response factor in the HPLC (calculated from standard solutions; for 4PyTP the molar 
extinction coefficient at 254 nm was calculated from solutions of known extinction and dry weight), 
the volume-equivalent of packed erythrocytes in the extracts applied to the column, and an estimate 
that 67% of the packed cell volume corresponds to cytoplasm. Our data therefore relate to the content 
of mature erythrocytes, and not to the actual haematocrit of the original blood samples. Toxins 2011, 3                    
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2.3. Identification of the Pyridine and Pyridone Bases and 4Py-Ribonucleoside in HPLC Profiles 
The elution profile of nucleotides analysed in anion-exchange HPLC has been well-characterised. 
The nucleotide that has now been identified as 4PyTP elutes after the distinctive peaks of ATP and 
GTP at the end of the rising gradient (see Figure 1).  
Figure  1.  Anion exchange HPLC analysis of erythrocyte extract from a patient in the 
―peritoneal‖ group. Nucleotides were separated on a Waters trimodule system with PDA 
detection from 230–310 nm. Extract (12 µL) was injected on to a 5 µm  NH2-2 hypersil 
column (250 ×  3.2 mm) ( Phenomenex) with a linear gradient from 100% Buffer A (5 mM 
sodium  phosphate,  pH  3.0),  to  40%  Buffer  B  (0.5  M  potassium  phosphate,  1.0  M 
potassium  chloride,  pH  3.3)  over  25  min,  a  run  time  to  33  min,  and  a  flow  rate  of  
0.5  mL/min.  Peaks  corresponding  to  2PY  (3.48  min),  NAD  (7.60  min)  and  4PyTP  
(27.65 min) are labelled, and their UV spectra are shown in the upper panels. ATP is the 
large peak eluting at approx 23.8 min: GTP elutes at 26.9 min. 
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The methylated pyridone bases were identified previously [3,4] by comparison with the NMR and 
mass  spectrometric  analysis  of  chemically  synthesized  2PY  and  4PY,  and  recognized  by  their 
characteristic  UV  absorption  spectra  (230–310  nm)  and  retention  times  in  reversed-phase  HPLC  
(see Figure 2).  
Figure  2.  Reverse-phase  HPLC  analysis  of  plasma  from  a  patient  in  the  ―peritoneal‖ 
group. The nucleosides and bases were separated by reverse phase HPLC, on a Waters 
Alliance system with PDA detection from 230–310 nm. Extract (25 µL) was injected on to 
a 5 µm ODS-1 Hypersil column (250 ×  3.2 mm) from Hichrom Ltd, with a linear gradient 
from  100%  Buffer  A  (40  mM  ammonium  acetate  pH  5.0),  to  20%  Buffer  B 
(methanol:tetrahydrofuran:acetonitrile  (80:10:10))  in  25  min,  with  a  flow  rate  of  0.5 
mL/min and a run time of 33 min. Peaks corresponding to 4Py-riboside (14.92 min), 2PY 
(16.69 min) and 4PY (19.56 min) are labelled on the chromatograph, and their UV spectra 
are shown in the upper panels.  
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The ribonucleoside of 4Py eluted at 14.5–15.5 min from the reversed-phase HPLC system used for 
plasma, and at 3.2–3.5 min when applied to the anion-exchange HPLC system used for analysis of the 
nucleotides. Its identity was confirmed by LC-MS as described below. The absorption spectrum of 
4Py-riboside was identical with a synthetic version, shown in supplementary material to reference 5; 
the nucleotides have similar spectra [3,5].  
2.4. Analysis of Plasma Samples by LC-MS 
A novel assay [5], using reverse-phase HPLC and mass detection, enabled closer examination of 
4Py-riboside, nicotinamide and N
1-methyl nicotinamide in plasma samples. The identities suggested 
from the characteristic UV spectra or retention times were confirmed by fragmentation pattern and 
mass detected in the positive ion mode. 
3. Results and Discussion 
3.1. Degree of Renal Failure and Uremia 
The children in this study all had poor kidney  function, shown by decreased filtration and the 
accumulation of creatinine, urea and uric acid in the plasma, which may affect the liver, kidney, brain 
and other organs. Similarly, metabolites of NAD
+ breakdown accumulated in parallel with the degree 
of renal failure because of poor filtration by the kidney (Table 1). In the children with the lowest 
degree of renal failure (calculated GFR above 72 mL/min/1.73 m
2), urea concentrations fell within the 
normal reference range but creatinine values were elevated. 
Children in end-stage renal failure, defined as GFR < 10 mL/min/1.73 m
2, received haemodialysis 
(HD) three times per week, or continuous ambulatory peritoneal dialysis (PD). Our blood samples 
were taken before haemodialysis, usually 2.5–3 days since the previous session; in this group (n = 6, 
―haemodialysis‖) the plasma concentrations of urea and creatinine were 5 to 10 times the levels found 
in healthy children. The PD patients (n = 6, ―peritoneal‖) were attending the morning out-patient  
clinic  and  thus  were  between  bag  changes;  urea  concentrations  resembled  those  in  children  with  
moderate-severe renal failure, but creatinine concentrations were grossly elevated (Table 1). 
Uric  acid  concentrations  in  our  patients  were  universally  elevated  above  the  reference  ranges, 
especially in  the plasma  of  HD patients (Table 1), but there was no  correlation with  GFR  in the  
non-dialysed  patients  (r  =  −0.077)  and  no  significant  difference  between  values  in  dialysed  and  
non-dialysed patients (Mann-Whitney test). 
3.2. Correlation of Methylated Pyridones and Tryptophan in Plasma with Severity of Renal Failure  
In the non-dialysis patients, there was a close correlation between the GFR and the logarithm of 
2PY concentration (r = −0.783, significant at the 0.01 level), and 4PY also accumulated but at much 
lower concentrations.  
Dialysis patients had creatinine concentrations above 600 μM, and 2PY above 30 μM, at the time of 
study. These values did not overlap with those of the other patient groups, who were well controlled 
with  creatinine  values  below  400  μM,  and  2PY  below  15  μM.  The  difference  between  the  2PY 
concentrations in the plasma of the dialysis patients and the non-dialysed patients was significant  Toxins 2011, 3                    
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(p  <  0.0005,  Mann-Whitney  test).  Compared  with  children  with  low-normal  renal  function  the 
concentrations of 2PY and 4PY were increased 13-fold and 39-fold respectively for the PD group, and 
20-fold and 58-fold for the HD group (Table 1). 
Circulating  levels  of  tryptophan,  the  amino  acid  precursor  for  de  novo  NAD
+  biosynthesis, 
correlated slightly with GFR (r = 0.574), being highest in the plasma of children with a high GFR and 
undetectable in some of the haemodialysis patients. Circulating tryptophan concentrations are known 
to fall in haemodialysis patients [9–11], and chronic renal failure causes a depletion of tryptophan in 
the plasma [12]. It has been reported that metabolites such as L-kynurenine and quinolinate from the  
de novo tryptophan-NAD
+ biosynthetic pathway [13,14] accumulate as a result of oxidative changes in 
the liver and kidney [15,16], displace the binding of tryptophan to human serum albumin [17,18] and 
contribute  to  some  of  the  symptoms  of  uraemia  in  the  circulation  and  brain  [10,11,19,20].  The 
measurement of these metabolites was outside the scope of this work. Total tryptophan values (free 
and protein-bound) in the plasma of healthy adults are reported to be 31.2 ±  7.4 μM [20], which was 
matched only by the children with lowest renal failure (Table 1). 
Table 1. Contents of plasma from children with renal failure. 
 
Low-Normal  
n = 5 
Mild  
n = 9 
Mod-Severe  
n = 8 
Peritoneal  
n = 6 
Haemodialysis  
n = 6 
GFR  95.00 ±  20.6  59.22 ±  5.26  34.75 ±  12.83  ≤10  ≤10 
Creatinine  95.8 ±  27.8  140.1 ±  27.4  248.5 ±  116.9  839.2 ±  223.9  1005.3 ±  258.6 
Urea  4.66 ±  1.25  8.42 ±  3.33  14.85 ±  5.19  13.80 ±  2.83  23.22 ±  3.03 
Uric acid  374.4 ±  56.4  454.3 ±  26.6  439.1 ±  19.5  426.2 ±  29.4  545.2 ±  51.1 
Tryptophan  31.79 ±  6.58  29.41 ±  8.21  18.80 ±  8.89  10.53 ±  6.84  4.96 ±  7.75 
2PY  2.55 ±  1.05  6.84 ±  3.38  10.84 ±  3.32  34.90 ±  8.23  53.38 ±  23.60 
4PY  0.16 ±  0.23  1.06 ±  0.79  1.77 ±  0.94  6.45 ±  1.01  9.50 ±  3.06 
Nicotinamide  0.38 ±  0.30  0.44 ±  0.19  0.57 ±  0.29  0.58 ±  0.40  0.94 ±  0.77 
N-Me-nic  0.05 ±  0.03  0.08 ±  0.03  0.06 ±  0.03  0.06 ±  0.03  0.14 ±  0.07 
4Py-riboside  0.03 ±  0.04  0.08 ±  0.08  0.10 ±  0.12  0.42 ±  0.23  0.28 ±  0.26 
Patients with chronic renal failure were assigned to groups according to calculated GFR or dialysis mode. 
The non-dialysis patients were divided empirically into three approximately equal groups: ―low-normal renal 
function‖ with GFR ≥ 71 mL/min/1.73 m
2 (actual range 72–120 mL/min/1.73 m
2 ); ―mild renal failure‖ with 
GFR 51–70 mL/min/1.73 m
2 (actual range 53–69 mL/min/1.73 m
2) and ―moderate-severe renal failure‖ with 
GFR ≤ 50 mL/min/1.73 m
2 (actual range 17–50 mL/min/1.73 m
2). 
The reference ranges for compounds in the plasma are: 2.5–6.0 mM urea for children aged 1–13 (2.5–7.5 mM over 
13 years); 30–65 μM creatinine for children aged 6–9 years, and 35–90 (100) μM for girls (boys) of 14–18 years. 
The reference range for uric acid in children of 7–10 years is 120–295 μM; at 12–16 years 180–345 μM 
(girls), 160–465 μM (boys). Each group (see Tables 1 and 2) contains children across the entire age range; 
The normal range of 2PY concentrations has been calculated, using a slightly different detection system, as 
0.39 ±  0.22 µM  in plasma of healthy children aged 5–16, and 1.01 ±  0.5 µM  in adults [10] while in our 
previous study [3] we estimated 9.0 ±  4.5 µM  in the plasma of healthy adults. 
Metabolites (mean ±  SD, concentrations expressed in μM, apart from urea mM) were identified and measured 
by HPLC as described in the text. 2PY and 4PY, N
1-methylated 2-pyridone and 4-pyridone respectively;  
N-Me-nic, N
1-methylnicotinamide. Toxins 2011, 3                    
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Nevertheless, the overall levels of NAD and NADP in the erythrocytes (Table 2) were not altered in 
the way expected if circulating tryptophan were a significant source for de novo synthesis. It was not 
possible to measure tryptophan stores in muscle or in the liver, where much of the NAD
+ synthesis 
takes place: however the children were well-nourished and would obtain both tryptophan and NAD
+ 
precursor vitamins [21] from the diet for de novo and salvage synthesis respectively.  
3.2.1. Renal Failure and the Accumulation of Methylated Pyridone and Pyridine Bases 
It is known that excess nicotinamide from the diet or released from NAD
+ (e.g.,
 through the activity 
of
  PARP-1,  sirtuin  or  NAD
+  glycohydrolase),  if  not  used  directly  in  recycling,  is  detoxified  by 
methylation at the N
1 position [22].  
Subsequent  attack  by  aldehyde  oxidase  in  the  human  liver  (Scheme  1)  modifies  
N
1-methylnicotinamide preferentially at the 2 position of the pyridine ring, resulting in a much higher 
concentration of 2PY than 4PY in the plasma and urine [23,24] as seen in Table 1. It can be seen that 
haemodialysis patients, who have the highest 2PY and 4PY values, also carry high concentrations of 
nicotinamide and N
1-methyl nicotinamide in the plasma, suggesting that the capacity of the oxidase 
reaction has been saturated. 
Scheme 1. Detoxification of excess nicotinamide. 
 
The human enzyme prefers substitution at the 2-position over the 4-position. 
Aldehyde oxidase is known to have a wide range of potential substrates, and the site of oxidation of 
nicotinamide  metabolites,  for  example,  is  moderated  by  substitution(s)  elsewhere  in  the  pyridine  
ring [25]. Concentrations of N
1-methylnicotinamide and the methylated pyridones, 2PY and 4PY, are 
usually low but detectable in the plasma of healthy subjects; they circulate freely in plasma without 
being bound to a carrier protein such as albumin. The observed rise in concentrations according to age 
reflects  the  known decline in  renal  function in adults [26], since these soluble metabolites would 
usually be excreted in the urine [27]. 
3.2.2. Presence of 2PY in Erythrocytes 
A peak eluting at 3.3 to 3.5 min from our anion exchange HPLC system has now been identified as 
2PY (it was erroneously reported earlier [6] to be the ribonucleoside related to 4PyTP) and has been Toxins 2011, 3                    
 
 
528 
found in the erythrocytes of all dialysis patients (Figure 1), but in only a small number of erythrocyte 
extracts from non-dialysed patients. In dialysis patients, where the concentration of 2PY in the plasma 
was already above 30 μM (Table 2), the concentration of 2PY in the red cells of each patient correlated 
closely  with  the  external  concentration  in  the  plasma  (r  =  0.845).  It  should  be  noted  that  no  
2Py-nucleoside has been observed. 
3.3. Concentration of Nucleotides in Erythrocytes: Correlation with Severity of Renal Failure 
As noted previously, 4PyTP remained in erythrocytes after artificial dialysis [3] and in this study we 
also confirm that high concentrations of 4PyTP correlate with decreases in the calculated GFR in 
children and are highest in dialysis patients (p < 0.0005 between dialysis and non-dialysis patients). As 
in our previous report on adult patients, the children undergoing peritoneal dialysis had very high mean 
concentrations of 4PyTP (200 μM) and 4PyDP (10 μM). Values for 4PyTP in the HD and PD groups 
differed significantly (p < 0.002) in the Mann-Whitney non-parametric test, being 3.7 and 9.7 times the 
concentration for children with low-normal renal function (Table 2). 
Table 2 shows that concentrations of other nucleotides were also elevated in erythrocytes: ATP 
showed a small rise associated with degree of renal failure, with a greater increase in the PD group. 
Concentrations of GTP were elevated in both dialysis groups.  
Table 2. Nucleotides in the erythrocytes of children with renal failure. 
 
Low-Normal  
n = 5 
Mild  
n = 9 
Mod-Severe  
n = 8 
Peritoneal  
n = 6 
Haemodialysis  
n = 6 
4PyTP  20.76 ±  5.85  28.96 ±  13.49  55.70 ±  31.28  200.57 ±  85.11  76.62 ±  25.00 
4PyDP  1.32 ±  1.44  2.34 ±  1.73  7.26 ±  6.59  10.38 ±  6.00  4.48 ±  5.42 
2PY  n.d.  n.d.  n.d.  10.5 ±  4.36  11.72 ±  8.46 
NAD  56.82 ±  6.79  59.74 ±  7.05  67.81 ±  6.16  72.90 ±  9.81  76.48 ±  13.35 
NADP  43.54 ±  2.61  48.8 ±  6.61  46.24 ±  3.53  47.55 ±  10.93  45.12 ±  4.40 
GTP  44.78 ±  2.62  44.31 ±  3.23  45.26 ±  4.82  88.63 ±  12.74  81.78 ±  27.57 * 
ATP  1222 ±  172  1350 ±  261  1486 ±  197  1754 ±  306  1449 ±  310 * 
* Omitting values from one patient, who was ITPase-deficient; 
Patients with chronic renal failure were assigned to groups according to calculated GFR or dialysis mode. See 
Table 1 for details; 
Metabolites (mean ±  SD, concentrations all expressed in μM) were identified and measured by HPLC as 
described in the text. 2PY, N
1-methylated 2-pyridone; 4PyTP and 4PyDP, triphosphate and diphosphate of  
4-pyridone-3-carboxamide-1β-D-ribonucleoside; n.d., not detected; NAD and NADP refer to sum of oxidized 
and reduced forms; 
The concentrations of nucleoside triphosphates in erythrocytes of healthy adult volunteers and unaffected 
relatives of renal patients [3] were 8.1 ±  3.4 µM  4PyTP, 39.0 ±  10.9 μM GTP and 1229 ±  184 μM ATP. 
3.4. Measurement of 4Py-Riboside in Plasma 
Plasma samples were analysed for 4Py-riboside using the LC-MS system [5], which enabled us to 
confirm the identity of the compound observed in the RPLC separation (Figure 2). There was a small 
increasing trend related to the degree of renal failure in the non-dialysis patients, and the compound was 
found at distinctly higher concentrations in the plasma of dialysis patients (Table 1). Children in the PD Toxins 2011, 3                    
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group had higher concentrations of the riboside in their plasma (0.42 ±  0.23 μM) than in the HD group 
(0.28 ±  0.26 μM), compared with 0.03 ±  0.04 μM for non-dialysed patients with severe renal failure. 
3.4.1. Correlation of 4Py-Riboside and 4PyTP Concentrations 
During the analysis of 4PyTP [5], pooled and purified from repeated HPLC runs of erythrocyte 
extracts of an adult PD patient, the ribonucleoside (4Py-riboside) was the sole digestion product after 
treatment with snake venom 5'-nucleotidase with or without purine nucleoside phosphorylase [28]. 
This  indicates  that  the  4Py-riboside  (unlike  NR  [29,30])  is  not  degraded  to  the  base  by  the 
phosphorylase, and explains why the related base, 4-pyridone-3-carboxamide, was never seen in the 
circulation.  We  have  established  that  4Py-riboside  is  the  authentic  precursor  of  4PyTP  [5],  being 
converted to the nucleotide after uptake into human erythrocytes. Thus the ribonucleoside circulates in 
the  plasma  until  taken  up  by  the  erythrocytes,  and  its  concentration  is  reflected  in  the  higher 
concentration of 4PyTP in dialysis patients.  
4Py-riboside,  described  as  PCNR  (4-pyridone  carboxamide  ribonucleoside),  has  been  isolated 
elsewhere from urine of leukaemia patients [31]. It occurs in the serum of reference populations in 
Italy and the USA [32] at approximately 60 nM, similar to the non-dialysed children in our study 
(Table 1). Its presence in the urine of patients with healthy kidneys is considered to be derived from 
turnover of NAD
+ and NADP, not from dietary nicotinamide [33]. In another study, we calculated the 
excretion of authentic 4Py-riboside as 26.7 ±  18.2 µmoles per day, equivalent to 13.6 ±  9.3 mg per 
day, from nine healthy subjects [5]. Elevated concentrations of 4Py-riboside, along with breakdown 
products of tRNA, report on the increased turnover of cells associated with cancer [34]. Patients with 
advanced HIV infection also have elevated plasma concentrations of approximately 74 nM [35], but 
this is much lower than the mean values of 420 nM in our PD patients and 280 nM in the HD group 
(Table  2).  The  higher  concentration  in  the  plasma  of  the  former,  compared  with  higher  2PY 
concentrations in HD patients, suggests that these two compounds are filtered differently, and also that 
4Py-riboside is protein-bound in the plasma. In patients relying upon artificial dialysis, we observe that 
all  intermediates  accumulate  to  such  high  concentrations  that  2PY  and  4Py-riboside  enter  the 
erythrocytes,  but  2PY  is  not  converted  further.  The  ribonucleoside  is  taken  up  rapidly  and 
phosphorylated  within  the  erythrocytes:  the  highest  concentration  of  4PyTP  is  found  in  the 
erythrocytes of PD patients, who also have the greatest relative increase of circulating 4Py-riboside.  
Normal breakdown of erythrocytes will release NAD
+ catabolites such as 4Py-riboside [34,35] and 
4PyTP, which may be converted back to 4Py-riboside in the plasma [5]; however, in the absence of 
normal excretion via urine, the intact erythrocytes in dialysis patients may pick up the circulating 
ribonucleoside and convert it back to 4PyTP. This model could explain why 4PyTP increases less in 
HD  erythrocytes  (3.7-fold)  compared  with  the  4Py-riboside  ratio  (9.3-fold)  in  plasma,  since 
mechanical haemodialysis is known to damage red cells, which thus also have a younger profile than 
the erythrocytes in PD patients.  
3.4.2. Origins of 4Py-Riboside 
We have observed, through analysis of many clinical samples over 25 years (LDF, HAS), that both 
2PY and 4PyTP are absent from the blood of subjects deficient in molybdenum cofactor, which is Toxins 2011, 3                    
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essential to the oxidases [36,25]; this strongly implicates aldehyde oxidase activity in the conversion of 
both  methylated  and  ribosylated  pyridines  into  the  respective  pyridones.  A  representative  clinical 
sample from a MoCo-deficient infant is illustrated in reference 3. In humans N
1-methylnicotinamide is 
converted to 2PY in great excess over 4PY [6,25], whereas the reverse is true in other mammals. Even 
when  4Py-riboside  is  found  in  significant  concentrations  in  the  plasma  of  renal  failure  patients, 
especially those with high levels of 4PyTP, we have not detected a 2-pyridone analogue. Early reports 
of the 2Py-riboside [22] were not confirmed, and a chemical analysis was not given; it may instead 
have been 4Py-riboside that was excreted at the rate of 5–10 mg per day in the urine of healthy adults, 
as in our study [5].  
Nicotinamide riboside (NR) is a chemically similar compound; it arises in a parallel pathway for 
NAD
+ breakdown in which NMN is released by the action of NAD
+ pyrophosphatase (EC 3.6.1.22) on 
NAD
+. This enzyme, and the NMN phosphohydrolase (EC 3.1.3.5) which generates the nicotinamide 
riboside, have been reported in human serum and may originate from the liver [37,38]. Alternatively, 
nicotinamide riboside (NR) has been described as a novel nutrient in milk [21], and may be excreted in  
the bile, if in excess [39]. It is a substrate for several enzymes in pathways leading to NAD
+ formation [21] 
and is thus a precursor vitamin. We have proposed a pathway (Scheme 2) in which NR is oxidised at 
the 4-position by aldehyde oxidase to yield 4Py-riboside. In healthy humans, the oxidation could also 
be a detoxification step, avoiding accumulation of excess nicotinamide, as in Scheme 1. 
Scheme 2. Role of aldehyde oxidase in the generation of 4Py-riboside. 
 
We have no direct evidence that aldehyde oxidase can convert NR into a pyridone riboside, nor that 
the 4-position is the only site of attack. However, in studies of the DNA methylation inhibitor zebularine 
(a pyrimidinone ribonucleoside), aldehyde oxidase from several mammalian species is shown to act at 
the 4-position of the pyrimidine ring, producing uridine [40]; this reaction is a direct parallel of the 
oxidation reaction proposed in Scheme II. It is entirely plausible that the presence of the ribose at N-1 
protects C-2 in NR from attack by human aldehyde oxidase. An alternative scheme is conceivable: 
oxidation of NAD
+ followed by direct cleavage by pyrophosphatase to generate 4Py-riboside. Toxins 2011, 3                    
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3.5. The “Paradoxical” Elevation of GTP Concentrations 
In this study, we observed elevated concentrations of GTP and ATP in the erythrocytes of dialysis 
patients (Table 2), where 4PyTP concentrations were highest. This is reminiscent of our study of adult 
renal transplant patients after several months’ immunosuppressive therapy with mycophenolate mofetil, 
where  we  observed  ―paradoxical‖  high  levels  of  GTP  (approx  146  μM)  in  the  erythrocytes  [41].  
We consider this to be a paradox since in other cells in the presence of mycophenolate mofetil, such as 
mononuclear leucocytes [42], the GTP concentrations are depleted: this is the expected result of the 
drug’s role as an inhibitor of the enzyme inosine monophosphate dehydrogenase (IMPDH), which is 
crucial in the synthesis of GTP and ATP. A similar increase in GTP (attributed to ―induction‖ of 
IMPDH)  was  observed  in  patients  treated  with  ribavirin  [43].  We  proposed  [41]  that  structural 
stabilisation, as described by  Nimmersgen et al. [44], of the IMPDH-inhibitor complex allowed a 
continuation of enzyme activity in non-nucleated mature erythrocytes, where new enzyme could not be 
synthesised. The analogy in this study would be that 4Py-riboside or the 4Py-nucleotides in patients 
with renal failure may bind specifically to IMPDH, stabilising the structure and activity in maturing 
erythrocytes, thus allowing GTP levels to increase slowly in these cells.  
We  were  able  to  perform  only  a  partial  enzymological  assessment  of  the  interaction  of  the  
4Py-riboside  and  4Py-nucleotides  with  IMPDH  (purified  from  platelets;  EAC,  LDF  preliminary 
results) because the putative inhibitors were in limited supply. We would predict that renal failure 
patients with high 4PyTP concentrations in the erythrocytes would have a higher IMPDH activity in 
these  cells,  alongside  depleted  GTP  and  IMPDH  in  lymphocytes.  In  vitro,  one  could  study  the 
interaction of the riboside and nucleotides with IMPDH using the biophysical methods described by 
Nimmersgen et al. [44]. 
3.6. Further Metabolism of 4Py-Ribonucleoside 
It has previously been demonstrated that 4Py-riboside is taken up into intact human erythrocytes  
in vitro in a reaction carried out by adenosine kinase since it is inhibited by 5'-iodotubericidin, with a 
net  consumption  of  ATP,  and  is  rapidly  converted  to  the  mononucleotide  and  4PyTP  [45].  The 
erythrocyte samples in this study showed a very high accumulation of 4PyTP and 4PyDP, reflecting 
the much longer timescale and equilibrium within cells obtained in vivo. Further studies in rodents 
have come to the intriguing conclusion that 4PyTP may be found only in erythrocytes: only 4PyMN 
was detected in the numerous other tissues that were investigated [46]. 
Once  again we are drawn to a comparison of 4Py-ribonucleotides and the known inhibitors of 
IMPDH. These inhibitors are especially useful in immunosuppression and the treatment of leukaemia 
because this enzyme  regulates cell proliferation through the supply of  the purine nucleotide GTP. 
Pharmaceutically-active  ribonucleoside  analogues  are  pro-drugs,  falling  broadly  into  two  classes, 
according to whether they are converted in vivo principally into toxic analogues of NAD
+ (tiazofurin, 
benzamide  riboside)  or  into  nucleoside  mono-,  di-  and triphosphates (ribavirin, viramidine)  which 
compete at the IMP binding site [47–51]. Sensitivity to these analogues therefore depends upon the 
expression in the cells of IMPDH [52], and requires NMN adenyltransferase [37,51,53] for conversion Toxins 2011, 3                    
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of the ribonucleoside to the dinucleotide. In sensitive lymphocytes, the concentration of GTP falls to 
unsustainably low levels [51,52] in the presence of tiazofurin anabolites. 
Tiazofurin is taken up into cells by facilitated nucleoside transport [53,54], competing with uridine. 
Further  metabolism  to  the  adenine  dinucleotide  TAD  (the  toxic  NAD
+  analogue)  occurs  in 
lymphocytes but, crucially, not in erythrocytes [55]. The NAD
+ analogue is a more effective inhibitor 
of IMPDH at low concentrations (Ki 0.13 µM). The ribonucleoside is phosphorylated by one or more 
of three enzymes [47]: adenosine kinase, NR-kinase or cytosolic 5'-nucleotidase. This is very similar to 
the conclusions we have drawn (above) about the further metabolism of 4Py-riboside. Conversion of 
tiazofurin to TAD [55,56] was observed in different cell types which were outside the scope of this 
study, and would therefore prevent us from observing a similar conversion of 4Py-riboside to an NAD
+ 
analogue. Within erythrocytes, nucleotides of ribavirin [49] and tiazofurin [57] have been shown to 
contribute to haemolytic anaemia, which is also a feature of uraemia. 
In Scheme 3 we summarise our current thinking about the further metabolism of 4Py-riboside, 
comparing it with the recycling of nicotinamide riboside (NR) and its conversion into NAD
+ (shown in 
black  on  the  top  line).  We  propose  that  4Py-riboside  enters  erythrocytes  and  other  cells  and  is 
immediately phosphorylated (shown in purple) by NR kinase (1) or adenosine kinase (3) to provide the 
4PyMN for further steps. Since NMN is converted to NAD
+ by (2) NMN-adenyltransferase [37], we 
are proposing that 4Py-riboside may also be converted to the NAD
+ analogue, here named as 4PyAD, 
by  a  similar  reaction  (shown  in  red)  in  lymphocytes  and  other  cells.  We  are  confident  that  in 
erythrocytes  the  mononucleotide  is  phosphorylated  (4)  to  the  nucleoside  triphosphate,  which 
accumulates to extremely high concentrations in end-stage chronic renal failure. 
Scheme 3. Further metabolism of 4Py-riboside to 4PyTP and to an NAD
+ analogue. 
 
4. Conclusions  
The compound that we have conclusively identified as 4-pyridone 3/5-carboxamide ribonucleoside 
triphosphate (4PyTP) was originally designated a ―uremic toxin‖ on the basis of its notable accumulation 
in a series of blood samples obtained from patients with chronic renal failure. The accumulation in the 
erythrocytes set it apart from the well-known methylated pyridones 2PY and 4PY, which are prominent 
in the plasma of renal failure patients. Like 2PY and 4PY, however, it is the product of the oxidizing Toxins 2011, 3                    
 
 
533 
conditions arising in renal failure, and its absence from erythrocytes of MoCo-deficient patients supports 
the mechanism involving aldehyde oxidase action on the nicotinamide riboside. This mechanism could 
be tested (if ethically approved) by treating patients with raloxifene, or 5-benzylacyclouridine, both of 
which prevented the action of aldehyde oxidase on zebularine [40]. 
The  toxic  nature  of  the  nucleotides  is  suggested  by  our  evidence  for  specific  binding  of  
4Py-riboside and 4PyMN to IMPDH from human platelets, leading to a small but consistent activation 
at the concentrations found in the erythrocytes of dialysis patients (4PyTP was not tested in this assay). 
Our work continues to elucidate whether, like tiazofurin, a more powerful toxicity is caused by an 
analogue of NAD
+ in cells of the immune system [55], or by hemolytic effects of the nucleoside 
triphosphate in the erythrocytes [57].  
Drugs Implicated in Inhibition of IMPDH 
Benzamide  riboside,  1-β-D-ribofuranosylbenzene-3-carboxamide;  MMF,  mycophenolate  mofetil, 
the  morpholinoethyl  ester  prodrug  of  mycophenolic  acid;  Ribavirin,  1-β-D-ribofuranosyl-1,2,4-
triazole-3-carboxamide; TAD, thiazole-4-carboxamide adenine dinucleotide (cf NAD); Tiazofurin, 2-β-D-
ribofuranosylthiazole-4-carboxamide; Viramidine, 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxoamidine. 
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